Transition Therapeutics granted patent for diabetes regenerative product E1-INT

By Elaine Rigoli

Tampa, Fla., Feb. 21 - Transition Therapeutics, Inc. announced the U.S. Patent and Trademark office issued patent No. 6,992,060 to the company. The claims in this patent cover methods of treating diabetes patients using Transition's lead diabetes regenerative product, E1-INT.

This patent issuance demonstrates Transition's ongoing strategy to aggressively pursue broad intellectual property protection of islet cell regenerative factors and their use in the treatment of diabetes, according to a company news release.

Transition now has seven issued patents for diabetes regenerative therapies and others pending in multiple jurisdictions throughout the world, the company said.

The INT technology platform is based on the discovery that a short course of injections of naturally occurring peptides can regenerate insulin-producing cells in the body.

Based in Toronto, Transition is a product-focused biopharmaceutical company, developing

novel therapeutics for disease indications with large markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.